Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Laminin-111 protein therapy enhances muscle regeneration and repair in the GRMD dog model of Duchenne muscular dystrophy.

Barraza-Flores P, Fontelonga TM, Wuebbles RD, Hermann HJ, Nunes AM, Kornegay JN, Burkin DJ.

Hum Mol Genet. 2019 Aug 15;28(16):2686-2695. doi: 10.1093/hmg/ddz086.

PMID:
31179490
2.

Sunitinib promotes myogenic regeneration and mitigates disease progression in the mdx mouse model of Duchenne muscular dystrophy.

Fontelonga TM, Jordan B, Nunes AM, Barraza-Flores P, Bolden N, Wuebbles RD, Griner LM, Hu X, Ferrer M, Marugan J, Southall N, Burkin DJ.

Hum Mol Genet. 2019 Jul 1;28(13):2120-2132. doi: 10.1093/hmg/ddz044.

PMID:
30806670
3.

Human Galectin-1 Improves Sarcolemma Stability and Muscle Vascularization in the mdx Mouse Model of Duchenne Muscular Dystrophy.

Wuebbles RD, Cruz V, Van Ry P, Barraza-Flores P, Brewer PD, Jones P, Burkin DJ.

Mol Ther Methods Clin Dev. 2019 Jan 22;13:145-153. doi: 10.1016/j.omtm.2019.01.004. eCollection 2019 Jun 14.

4.

SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy.

Sarathy A, Wuebbles RD, Fontelonga TM, Tarchione AR, Mathews Griner LA, Heredia DJ, Nunes AM, Duan S, Brewer PD, Van Ry T, Hennig GW, Gould TW, Dulcey AE, Wang A, Xu X, Chen CZ, Hu X, Zheng W, Southall N, Ferrer M, Marugan J, Burkin DJ.

Mol Ther. 2017 Jun 7;25(6):1395-1407. doi: 10.1016/j.ymthe.2017.03.022. Epub 2017 Apr 5.

5.

Impaired fetal muscle development and JAK-STAT activation mark disease onset and progression in a mouse model for merosin-deficient congenital muscular dystrophy.

Nunes AM, Wuebbles RD, Sarathy A, Fontelonga TM, Deries M, Burkin DJ, Thorsteinsdóttir S.

Hum Mol Genet. 2017 Jun 1;26(11):2018-2033. doi: 10.1093/hmg/ddx083.

6.

Galectin-1 Protein Therapy Prevents Pathology and Improves Muscle Function in the mdx Mouse Model of Duchenne Muscular Dystrophy.

Van Ry PM, Wuebbles RD, Key M, Burkin DJ.

Mol Ther. 2015 Aug;23(8):1285-1297. doi: 10.1038/mt.2015.105. Epub 2015 Jun 8.

7.

Levels of α7 integrin and laminin-α2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy.

Wuebbles RD, Sarathy A, Kornegay JN, Burkin DJ.

Dis Model Mech. 2013 Sep;6(5):1175-84. doi: 10.1242/dmm.012211. Epub 2013 Jul 11.

8.

A molecular bandage for diseased muscle.

Burkin DJ, Wuebbles RD.

Sci Transl Med. 2012 Jun 20;4(139):139fs19. doi: 10.1126/scitranslmed.3004082.

PMID:
22723460
9.

Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy.

Rooney JE, Knapp JR, Hodges BL, Wuebbles RD, Burkin DJ.

Am J Pathol. 2012 Apr;180(4):1593-602. doi: 10.1016/j.ajpath.2011.12.019. Epub 2012 Feb 6.

10.

Transgenic overexpression of the α7 integrin reduces muscle pathology and improves viability in the dy(W) mouse model of merosin-deficient congenital muscular dystrophy type 1A.

Doe JA, Wuebbles RD, Allred ET, Rooney JE, Elorza M, Burkin DJ.

J Cell Sci. 2011 Jul 1;124(Pt 13):2287-97. doi: 10.1242/jcs.083311. Epub 2011 Jun 7.

11.

Testing the effects of FSHD candidate gene expression in vertebrate muscle development.

Wuebbles RD, Long SW, Hanel ML, Jones PL.

Int J Clin Exp Pathol. 2010 Mar 28;3(4):386-400.

12.

FSHD region gene 1 (FRG1) is crucial for angiogenesis linking FRG1 to facioscapulohumeral muscular dystrophy-associated vasculopathy.

Wuebbles RD, Hanel ML, Jones PL.

Dis Model Mech. 2009 May-Jun;2(5-6):267-74. doi: 10.1242/dmm.002261. Epub 2009 Apr 21.

13.

Muscular dystrophy candidate gene FRG1 is critical for muscle development.

Hanel ML, Wuebbles RD, Jones PL.

Dev Dyn. 2009 Jun;238(6):1502-12. doi: 10.1002/dvdy.21830.

14.

DNA repair in a chromatin environment.

Wuebbles RD, Jones PL.

Cell Mol Life Sci. 2004 Sep;61(17):2148-53. Review.

PMID:
15338044

Supplemental Content

Loading ...
Support Center